On November 1, during the 2nd China Healthcare Industry
Investment Summit, managers from various international venture
investment funds (VIF) expressed their interest in the Chinese
pharmaceutical industry.
Norman Chen, a partner with Fidelity Asia Ventures, cited many
favorable elements in the Chinese drug development business, such
as a large number of trial subjects, relatively low salaries of
medical research staff, cheap labor, and low costs.
Wu Rong, a manager from Intel Capital, added that the Chinese
government has more favorable policies than the US government in
terms of management and supervision over the pharmaceutical
industry.
However, some managers are not so upbeat about the investment
prospects in the industry. Joe Zhou, a partner with KPCB China said
that it is very difficult for VIFs to assess the marketing
prospects of newly developed drugs and capacities of drug research
institutes without efficient pharmaceutical
knowledge.??????
For more details, please read the full story in Chinese. (
http://jjckb.xinhuanet.com/gnyw/2007-11/05/content_72512.htm)
(China.org.cn November 5, 2007)
